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Nowadays etiology and pat�ogenesis of ovarian 
cancer �OC�� remain still unclear. T�e risk factors of t�is 
pat�ology include age and peculiarities of reproductive 
function�� �ormone factors�� especially estrogens and pro-
gesterone level�� �armful environmental influence [1].
�any of current studies focus on t�e involvement 
of oncogenic viruses �t�e Eps�teine-Barr virus�� Hu-
man Papilloma virus type 16�� 18�� �8�� �6�� Herpes virus�� 
Cytomegalovirus and TT-virus�� and bacterial infec-
tions �Chlamydia trachomatis, Mycoplasma spp., 
Ureaplasma urealiticum�� in t�e occurrence of epit�elial 
ovarian tumors [�]. 
Besides�� referred above suc� genetic factors as 
function of tumor suppressor genes and DNA reparation 
genes play an important and maybe  t�e main role in OC 
origin [�]. Application of molecular-biological met�ods 
into oncology contributed to forming t�e concept about 
presence of certain expression profile in tumors of dif-
ferent origin. Recently�� a group of ovarian tumors wit� 
�ig� cell cycle genes expression was distinguis�ed.  Ac-
cording to t�e literature data�� about 8�.�% of �ereditary 
OC forms are accompanied by alterations in BRCA1 and 
BRCA2 genes �in some cases in bot� genes simultane-
ously���� w�ic� are caused by germline and somatic muta-
tions�� loss of �eterozygosity or aberrated met�ylation of 
CpG islands in promotor region [�]. �et�ylation of CpG 
islands is proved to be one of t�e main ways of inactiva-
tion of suppressor genes in OC [�]. 
�any aut�ors s�owed t�at mutation of ТР53 tumor 
suppressor gene is t�e most frequent genetic feature 
in sporadic cancer forms �about ��.�% of cases�� [�]. 
T�e number of cases wit� mutated ТР53 among ovar-
ian serous carcinomas and endometrioid malignant 
tumors is ���.�% and ��.�% respectively wit� maximum 
value in poorly differentiated tumors in patients wit� III 
or IV stage of disease. Ovarian serous carcinomas �ave 
mutated ТР53 gene even at t�e initial stage of illness. 
T�e missense mutation in specific DNA-binding domains 
leads to cancer development in t�e most cases because 
of t�e  loss of normal р�� function. W�en wild type and 
mutated alleles of ТР53 gene are bot� present in t�e cell�� 
t�e respective products may form an oligomeric protein 
complex. T�is p�enomenon is called “dominant-negative 
effect of ТР53 mutation” [6]. In t�is case�� wild type р�� 
can be only partly inactivated and detected by immuno-
�istoc�emistry. Anot�er type of ТР53 mutation resulting in 
t�e loss of gene’s functional activity is premature stop co-
don �nonsense mutation��. Protein products of suc� genes 
cannot be detected by immuno�istoc�emistry [��]. 
One of t�e main р�� effectors is р�1WAF1/CIP1 gene — t�e 
cyclin-dependent kinases in�ibitor from CIP/KIP family. 
T�e product of t�is gene is р�1WAF1/CIP1 protein�� w�ic� is 
able to in�ibit proliferation during almost all cell cycle 
p�ases �G1�� S and G���. T�e р�1WAF1/CIP1 protein is acti-
vated by р�� protein encoded by wild�� but not mutant 
TP�� type. From ot�er �and�� t�e increase of р�1WAF1/CIP1 
expression under t�e presence of mutant ТР�� can 
evidence on р��-independent pat�way of regulation of 
р�1WAF1/CIP1 expression �e. g. by t�e protein products of 
BRCA1, WT1, ТР63 genes or by progesterone�� [8�1�].
Some researc�ers considered t�at t�e c�anges 
in p16INK4a gene functions �ave great significance 
in OC pat�ogenesis as well [11�1�]. T�e mutations 
of t�is gene usually appear on t�e early stages of 
transformation of ovarian epit�elium [1�]. First of all�� 
t�e occurrence of neoplasia is caused by deletion in 
�q�1 region�� w�ere р16INK4а gene is located and by 
�ypermet�ylation of р16INK4а promotor region. If t�e 
mutant gene is �eterozygous�� anot�er allele�� w�ic� 
is not mutated�� continues to work as suppressor 
and t�e cell can function wit�out abnormalities for a 
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w�ile. However�� �ypermet�ylation of even one allele of 
p16INK4а gene makes cell be susceptible to malignant 
transformation. Loss of p16INK4a in�ibitory function oc-
curs in ��.�% of serous and 1��.�% of mucinous ovarian 
tumors and is more likely for tumor cells wit� wild type 
ТР53 (approximately ��.�% of tumors �ave wild type 
and �6.�% mutant ТР53�� [11�� 1�]. 
As ovarian epit�elial cells undergo transformation�� 
t�ere are not only alteration in ТР53 suppressor gene�� 
but abnormalities of regulator cell cycle genes as well 
�p16INK4a, р21WAF1/CIP1, р27KIP1, р14ARF and ot�ers��.
Taking into consideration all mentioned data�� t�e 
aim of our study was to investigate t�e р���� р�1WAF1/CIP1�� 
р16INK�a and Кі-6�� expression in serous ovarian carci-
nomas of different grade.
MATERIAL AND METHODS 
In t�e study�� t�e surgical material of �� patients 
wit� OC of I�IV stages was used. T�e age of t�e pa-
tients ranged from �1 to ��6 years�� wit� a mean value 
of �1.� ± �.�. T�e unaltered epit�elial ovarian tissue 
from 8 women wit� mean age ��.� ± �.� ������� years 
old���� w�ic� underwent surgery for uterine fibromyoma�� 
was used as relative control. All patients were cured in 
t�e Department of Oncogynecology�� Institute of On-
cology�� A�S of Ukraine �t�e Head of t�e Department 
is prof. L.I. Vorobyova��. T�e informed consent of all 
patients �as been received.
Processing of operation material�� immuno�is-
toc�emical detection and evaluation of biomarkers 
expression and statistic analysis of obtained results 
were accomplis�ed according to t�e standard proce-
dure [1��� 16] wit� modifications of our laboratory [1��]. 
Histologic diagnosis was performed according to t�e 
criteria of t�e World Healt� Organization [18]. 
T�e operation material was fixed in 1�% neutral 
formalin solution and processed for embedding in 
paraffin wax. T�e �istologic diagnosis was verified by 
studying �ematoxylin & eosin stained sections. T�e 
immuno�istoc�emical detection of biomarkers was 
conducted using monoclonal primary antibodies �Da-
koCytomation�� Denmark��: anti-Ki-6�� — �IB-1 clone; 
anti-р�� — DO-�� clone; anti-р�1WAF1/CIP1 — SX118 clone 
and anti-р16INK�a — CINtectm clone. Reaction was visu-
alized by EnVision system wit� next DAB staining. Cell 
nuclei were conterstained by �ayer’s �ematoxylin. 
T�e results of immuno�istoc�emistry were evaluated 
semiquantitatively via calculation of positively stained 
cells �labelling index — LI��. T�e expression of markers 
was evaluated in 6������� tumor cells. T�e statistic 
met�od of median �Ме�� determination for eac� single 
parameter was used for correct interpretation of evalu-
ation of t�e biomolecular markers expression. We �ave 
found t�at р�1WAF1/CIP1 median is ��.�%�� р16INK�a = 1����% 
and р�� = ��.�%. According to t�ese results t�e criteria 
for evaluation of markers expression were t�e follow-
ing: t�e protein expression level was considered as low 
if LI < 1�.�% for р�� and p16INK�a�� and if LI < ��.�% for 
p�1WAF1/CIP1; and as �ig� if 1�.�% ≤ LI < ��.�% for р���� 
1�.�% ≤ LI < ��.�% for p16INK�a and ��.�% ≤ LI < 1�.�% 
for p�1WAF1/CIP1. T�e criteria for protein overexpression 
were LI ≥ ��.�% for р��; LI ≥ ��.�% for p16INK�a and 
LI ≥ 1�.�% for p�1WAF1/CIP1. T�e proliferative potential 
was determined according to t�e number of Кі-6��-
positive cells: PI < 1�.�% — low proliferative activity�� 
PI ≥ 1�.�% — �ig� level of proliferation. 
RESULTS
 By �istologic differentiation�� adenocarcinomas were 
subclassified into Grade I �G1�� n = 8���� Grade II �G��� n = 1��� 
and Grade III �G��� n = ����. Immuno�istoc�emical inves-
tigation s�owed a lack of Кі-6���� р���� р�1WAF1/CIP1 and 
р16INK�a expression �except some cases�� in epit�elial 
cells of ovarian normal tissue. In contrast to normal 
tissue�� t�e expression of t�ese markers was observed 
in t�e most of ovarian carcinomas �Table 1��. 
Тable 1. The level of expression of biomolecular markers in ovarian 
adenocarcinomas with different histologic grade
Pathohis-
tological 
diagnosis 
The  
number 
of pa-
tients
The number of positive cells, %, 
Ki-67 р53 р21WAF1/CIP1 р16INK4a 
Unaltered 
ovarian 
tissue
8 1.0 (1 case) 0 0 5.0 
(1 case) 
Adenocar-
cinomas
43 30.0 ± 0.3
(18.0–76.3)
40.3 ± 0.3 
(6.7–72.5)
6.8 ± 0.3 
(0–31.3)
31.1 ± 0,6
(0–66.7)
G1 8 14.0 ± 0.4 
(18.0–28.8)
34.9 ± 0.7
(22.8–38.6)
9.4 ± 0.8
 (0–31.3)
11.0 ± 0.8 
(0–34.5) 
G2 15 32.4 ± 0.5 
(18.0–58.7)
37.0 ± 0.5
(12.6–70.0)
8.1 ± 0.8
 (0–28.2)
27.0 ± 0.8 
(0–42.2
G3 20 37.1 ± 0.4
(20.9–76.3)
45.8 ± 0.5
(6.7–72.5)
3.4 ± 0.3
(0–11.0)
35.9 ± 0.3
(0–66.7)
As s�own in Table 1�� proliferative potential of malig-
nant ovarian tumors as well as р���� р16INK�a expression 
were �ig�. �eanw�ile t�e level of p�1WAF1/CIP1 expression 
was low �Figure��. Wit� lowering of degree of differen-
tiation ovarian tumor t�e quantity of proliferating cells 
increased. Similarly�� t�e increase of t�e quantity of р�� 
and р16INK�a positive cells was detected in less differenti-
ated ovarian tumors. At t�e same time t�e percentage 
of cells wit� p�1WAF1/CIP1 expression in G1 and G� ovarian 
adenocarcinomas was low and decreased significantly 
in G� tumors �up to ��� �%��.
Expression of some biomolecular markers in OC tu-
mors of certain �istologic grade is s�own in Table �.
Tаble 2. Expression of biomolecular markers in OC tumors 
of different grade
The expression 
level of biomolecu-
lar markers
Ovarian adenocar-
cinomas (the num-
ber of cases, %)
The grade of differentiation 
(the number of cases, %)  
G1 G2 G3
р53 
Low
High
Overexpression
7.3
19.5
73.2
0
25.0
75.0
6.7
33.3
60.0
11.1
5.6
83.3
р21WAF1/CIP1
Low
High
Overexpression
66.7
25.0
8.3
60.0
20.0
20.0
62.5
25.0
12.5
72.7
27.3
0
р16INK4a
Low
High
Overexpression
25.0
8.3
66.7
75.0
0
25.0
20.0
10.0
70.0
9.1
9.1
81.8
Кі-67
Low
High
11.6
88.4
37.5
62.5
13.3
86.7
0
100.0
T�e most of ovarian adenocarcinomas �88.�%�� were 
�ig�-proliferating tumors. T�e p�� expression was ob-
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served in 1��% of ovarian tumors and was mainly �ig� 
and very �ig� �in ��.��% of investigated tumors��. 
T�e expression of p�1WAF1/CIP1 protein was revealed 
in 6�.�% of tumors�� but t�e �ig� expression level  was 
detected only in ��.�% and overexpression — in 8.�% of 
cases. T�e р16INK�a expression was determined in 8�.�% 
of ovarian tumors and its overexpression was prevalent 
�66.��% cases��. It is necessary to mark t�e inverse relation 
between biomolecular markers overexpression and t�e 
grade of ovarian adenocarcinomas differentiation. 
T�e decrease of a �istologic grade of ovarian tumor 
cells was associated wit� increase in quantity of cases 
wit� p�� and р16INK�a overexpression and �ig� level 
of proliferative activity�� reac�ing t�e maximum in G� 
�8�.��� 81.8 and 1��%�� respectively��. In contrast to it�� 
t�e number of cases wit� р�1WAF1/CIP1 overexpression 
was t�e �ig�est in G1�� decreased in G� and wasn’t 
revealed in G� tumors. 
DISCUSSION
T�e results of our researc� �ave revealed t�at t�e 
malignant ovarian tumors are c�aracterized by t�e 
significant proliferative activity and level of р�� and 
p16INK�a expression. At t�e same time t�ese tumors were 
c�aracterized by low p�1WAF1/CIP1expression. T�e maxi-
mal values of Кі-6���� р�� and p16INK�a and t�e minimal 
values of p�1WAF1/CIP1 expression were determinated in 
G� ovarian tumors. It is possible t�at suc� decrease 
of p�1WAF1/CIP1 expression may be a result of a lack of 
transactivating influence of p�� protein on p21WAF1/CIP1 
gene. Summing up t�e carried out researc��� it is neces-
sary to mark t�at t�e c�anges of expression of studied 
proteins�� w�ic� were determined by us�� coincided wit� 
t�e data of ot�er aut�ors [���1�]. In t�ose studies were 
described t�at p��-dependent pat�way of p�1WAF1/CIP1 
activation is preserved only in clear cell and endometri-
oid ovarian carcinomas but disrupted in t�e most serous 
carcinomas�� presumably associated wit� t�e loss of 
normal p�� function. In ot�er words�� in serous ovarian 
carcinomas t�e activation of p21WAF1/CIP1 gene occurs by 
p��-dependent pat�way and expression of p�1WAF1/CIP1 
protein determinates t�e activity of Cdk complex — D1-
D�/Cdk��� Cdk6 and proliferative potential of ovarian 
cancer�� at t�e same time t�e �ig� proliferative activity 
in ovarian tumors caused by t�e low level of p�1WAF1/CIP1 
expression [1�]. T�is conclusion is in line wit� our finding 
t�at G� tumors wit� a �ig� level of p�� accumulation ex-
press p�1WAF1/CIP1 at low levels. It �as been s�own t�at t�e 
patients wit� p�1+р�� - p�enotype �ave more favorable 
prognosis t�an t�e patients wit� p�1- р��+ p�enotype�� 
and t�e determination of p�1WAF1/CIP1/р�� p�enotype is 
better prognostic c�aracteristics in patients wit� ovarian 
cancer t�an separate determination of level of t�ese 
markers expression.
One more reason for derangements of p�1WAF1/CIP1 
and р�� proteins functioning can be ВRCA1 gene 
Figure. Immuno�istoc�emical detection of expression of Кі-6�� in G� �а���� p�� in G� �b���� p�1WAF1/CIP1 in G� �c�� and p16INK�a in G1 �d�� 
serous ovarian adenocarcinomas. Original magnification x ��� �a, b, d�� and x ��� �c��
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mutations �trans-activator of ТР53 and p21WAF1/CIP1 
genes���� w�ic� are frequent event in �ereditary ovarian 
cancer. Alt�oug� t�ey �ave generally been considered 
to �ave more limited roles in sporadic ovarian cancer 
t�ere are data according to w�ic� t�e mutations at bot� 
genes ТР53 and ВRCA1�� w�ic� are associated wit� a 
decrease of ВRCA1 expression in sporadic ovarian 
cancers are observed [1�]. On t�e ot�er �and�� several 
reports �ave focused on cell signal cascades�� w�ic� 
occur wit� ТР53 participation and are often interrelated 
wit� signal pat�ways t�at are regulated by RB gene. 
�utative events or c�anges of pat�ways of ТР53 and 
RB are observed in more t�an 8�% of malignant tumors 
[��]. It is known t�at some factors can cause t�e RB 
inactivation: partial loss of �eterozygosity of RB-locus�� 
t�e increase of expression of cyclins and cyclin-depen-
dent kinases of serous tumors of ovary is associated 
wit� p16INK4a gene overexpression�� probably reflecting 
accumulation of inactive p16INK4a products [1�]. It can 
be a result of carcinogenic action of Herpes and Hu-
man Papilloma �HPV�� viruses since viral infection con-
tributes to significant increase of p16INK4a expression 
[�]. At t�e same time t�ere were data about one more 
mec�anism of simultaneous suppression of рRb�� р�� 
and p�1WAF1/CIP1 proteins by formation of inactivating 
complexes between t�em and E6�� E�� HPV oncopro-
teins �for 16 and 18 HPV types�� [��]. T�e functional 
in�ibition of Cdk’ in�ibitors by viral oncoproteins may 
allow t�ese viruses to promote constitutive activation 
of cyclin-Cdk complexes and cell cycle progression. 
T�e E6 protein binds and inactivates р�� and E�� — pRb 
protein t�at can cause t�e proteolytic degradation of 
t�ese suppressors and release of E�F transcriptional 
factor. E�� destabilizes pRB by induction its degrada-
tion via an ubiquitin-proteosome pat�way. E�F can 
activate p16MTS/INK4a gene transcription and cause sud-
den increase of p16INK�a expression. Besides�� E�� can 
also bind and inactivate Cdk in�ibitors p�1WAF1/CIP1 and 
p���КIP1�� t�us providing anot�er mec�anism t�roug� 
w�ic� E�� can disrupt t�ese cellular processes. E�� 
also interacts indirectly wit� cyclin E-Cdk��� mediated 
t�roug� p1����� pRb-related proteins. T�e significant 
distinctions of р�� and p�1WAF1/CIP1 expression were 
observed in HPV16-positive and negative tumors in 
patients wit� breast cancer [��]. It �as been s�own 
t�at t�e level of р�� and p�1WAF1/CIP1expression was sig-
nificantly lower �or was absent�� in t�e most of HPV16-
positive carcinomas and on t�e contrary — HPV16-
negative tumors �ad mainly �ig� expression level of 
р�� and p�1WAF1/CIP1 proteins. Considering t�e fact t�at 
t�ese viral oncoproteins inactivate and degrade t�e 
р�� and p�1WAF1/CIP1 proteins�� t�ese data indicate t�e 
resistance of p�� mutant protein to HPV16 action.
In conclusion�� our present data demonstrate t�at 
Кі-6���� р���� p�1WAF1/CIP1 and р16INK�a proteins are differ-
ently expressed in normal ovarian surface epit�elium 
and ovarian serous adenocarcinomas�� t�at can be 
used for differential diagnostics of ovarian malignant 
process. 
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ЭКСПРЕССИЯ БЕЛКОВ p53, p21WAF1/CIP1, p16INK4A И Ki-67 
В СЕРОЗНЫХ ОПУХОЛЯХ ЯИЧНИКА
Цель: анализ экспрессии белков р53, р21WAF1/CIP1, р16INK4a и Кі-67 в серозных опухолях яичника разной степени дифференциации. 
Материалы и методы: иммуногистохимическое определение уровня экспрессии белков Кі-67, р53, р21WAF1/CIP1 и р16INK4a в 
образцах операционного материала 43 больных раком яичника и 8 пациенток с фибромиомой матки, эпителиальная ткань 
яичника которых не изменена. Результаты: установлено, что в неизмененном поверхностном эпителии яичников экспрессия 
белков Кі-67, р53, р21WAF1/CIP1 и р16INK4a  не выявлялась. �ля серозных аденокарцином характерна высокая пролиферативная ак-      
тивность (индекс пролиферации (ИП) Кі-67 = 30,0 ± 0,3%), гиперэкспрессия р53 (индекс метки (ИМ) = 40,3 ± 0,3%) и р16INK4a 
(ИМ = 31,1 ± 0,6%), а также низкий уровень экспрессии р21WAF1/CIP1 (ИМ = 6,8 ± 0,3%). �становлена зависимость уровня   
экспрессии изученных маркеров от степени дифференцировки серозных опухолей яичника: максимальный уровень экспрессии 
Кі-67, р53 и p16/INK4a и минимальный p21WAF1/CIP1 отмечали в низкодифференцированных аденокарциномах яичника. Таким 
образом, низкий уровень экспрессии белка p21WAF1/CIP1 (ИМ < 7,0%) с одновременной гиперэкспрессией р16INK4a можно считать 
фактором неблагоприятного течения серозного рака яичника. Выводы: результаты проведенного исследования показали, что 
молекулярно-биологические маркеры пролиферации клеток наряду с традиционными клиническими и морфологическими 
характеристиками могут быть использованы для дифференциальной диагностики опухолевого процесса в яичнике.
Ключевые слова: рак яичника, степень дифференцировки, экспрессия биомолекулярных маркеров, Кі-67, р53, p21WAF1/CIP1 
и p16/INK4a.
